.png){kind=logo}
US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.
Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.
HOW WE USE YOUR INFORMATION
-
to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
-
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
-
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;
-
to send marketing communications to you, if applicable and
-
to comply with our legal and regulatory obligations and bring and defend legal claims.
We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein).
We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.
If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
Novagali
Sold to Santen Pharma for $139M in 2011
Japan’s Santen has engineered a pact to buy up the French biotech Novagali Pharma and its ophthalmology pipeline in a deal worth about $139 million for its investors. Novagali, which is helmed by French scientist Jerome Martinez, has been developing a late-stage drug that promises to rival Allergan’s Restasis, which earned $620 million in 2010.
The buyer structured the deal to acquire slightly more than half of Novagali’s shares at €6.15 each–snapping up shares held by Edmond de Rothschild, Auriga Partners, IdInvest Partners and CDC Innovation for a hefty 71% premium. They then plan to offer a tender offer for the remaining shares, paying a small bonus for all the shares once they line up 95% of the stock. In addition to its experimental drugs in the pipeline, Novagali has a marketed drug-Cationorm-on the market.
The buyout gives Rothschild’s and the other investors a clean cash exit, which is rather rare these days for a biotech with a pipeline of experimental meds. Rothschild’s has been scouting around for new investors interested in backing a new fund.
One of Novagali’s prime assets is the Phase III dry eye treatment Cyclokat.
Investigators began recruiting patients for the late-stage treatment last spring, looking to demonstrate that the biotech’s absorption optimizing tech would prove effective in a once-daily treatment for severe dry eye. Santen is banking that the drug will get flagged for approval, adding to its lineup of ophthalmology treatments as the world’s population ages, suffering from the corrosive effects of pollution and over-exposure to computer screens.
“Santen believes that by acquiring Novagali, it will be able to strengthen its global business platform, which is one of the key strategic focus of its long term vision for 2020 as well as its medium-term management plan for 2011-2013,” said Santen CEO Akira Kurokawa.
The buyout gives Rothschild’s and the other investors a clean cash exit, which is rather rare these days for a biotech with a pipeline of experimental meds.
Learn more here.